Shares of Adherex Technologies Inc. (NASDAQ:FENC – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $15.40.
Several equities analysts recently commented on FENC shares. Wall Street Zen upgraded Adherex Technologies from a “hold” rating to a “strong-buy” rating in a research note on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adherex Technologies in a research note on Friday, July 17th. Wedbush restated an “outperform” rating and issued a $13.00 price target on shares of Adherex Technologies in a report on Thursday, April 16th. Zacks Research raised shares of Adherex Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. Finally, HC Wainwright increased their price objective on shares of Adherex Technologies from $13.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, May 22nd.
View Our Latest Stock Analysis on FENC
Adherex Technologies Stock Performance
Adherex Technologies (NASDAQ:FENC – Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. Adherex Technologies had a negative return on equity of 43.87% and a negative net margin of 17.12%.The company had revenue of $15.11 million during the quarter, compared to the consensus estimate of $13.90 million. As a group, equities analysts predict that Adherex Technologies will post 0.26 EPS for the current year.
Hedge Funds Weigh In On Adherex Technologies
A hedge fund recently bought a new position in Adherex Technologies stock. AQR Capital Management LLC acquired a new stake in shares of Adherex Technologies Inc. (NASDAQ:FENC – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,897 shares of the company’s stock, valued at approximately $66,000. 55.51% of the stock is owned by institutional investors.
Adherex Technologies Company Profile
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.
Featured Stories
- Five stocks we like better than Adherex Technologies
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
